Lymphoma 2022 Virtual Conference: State-of-the-Art and Future Directions

Date : 24th February 2022 to 24th February 2022

Place : Israel, Jerusalem

Website :https://lymphoma2022.com/

Contact Person:Rosemarie Dotorovici Liberman

Description:

It is our great pleasure to welcome you to the Lymphoma 2022 Virtual Conference: State-of-the-Art and Future Directions which will take place February 24th, 2022. The aims of this conference are to present a state-of-the-art update on etiology and genomics of lymphoma, to discuss novel therapies recently approved or currently evaluated for lymphoma treatments and to summarize the current knowledge and future directions in treatment of most common lymphomas. The lectures will be presented by international lymphoma experts. This Conference will welcome hematologists, healthcare clinicians, hematologic oncologists, medical, radiation and surgical oncologists, physicians, oncology nurses, nurse practitioners, occupational therapists, researchers, pharmacists and other healthcare professionals working in the fields of oncology and hematology. The Conference will focus on the following key areas: . Genomics of lymphoma . Novel therapies in lymphoma, including Car-T, bispecific antibodies, ADCs and NK Cars . Current treatment paradigms of most common lymphomas and ongoing clinical trials Share your research by submitting an abstract for e-poster presentation. Join us as a Sponsor or Exhibitor and benefit from maximum visibility and exposure to a broader audience. We look forward to seeing you at Lymphoma 2022 Virtual Conference: State-of-the-Art and Future Directions. Izidore S. Lossos M.D. Conference Chair

Lymphoma 2022 Virtual Conference: State-of-the-Art and Future Directions will be held in Jerusalem,Israel on date 2022-02-24

---

Deadline for abstracts/proposals : 13th January 2022

Keynote Speakers :

Conference Highlights :. Genomics of lymphoma . Novel therapies in lymphoma, including Car-T, bispecific antibodies, ADCs and NK Cars . Current treatment paradigms of most common lymphomas and ongoing clinical trials

Check the event website for more details.